NEO NeoGenomics, Inc. - Common Stock
NASDAQ · Health Care · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 七月 28, 2026
$18.47
· % 处于52周区间
· 高于低点
· 至高点
$7.0752周低点
$20.0552周高点
市值 (MRQ)
$2.36B
P/E
-77.9
收入
$727M
NEO 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$18.47
市值 (MRQ)
$2.36B
P/E
-77.9
收入
$727M
ROE
-12.8%
负债/权益 (MRQ)
0.5
52周区间
$7–$20
NEO 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
关于 NeoGenomics, Inc. - Common Stock 公司概况（来自维基百科）
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.
Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US, with laboratories in Florida, California, Tennessee, and Texas.
## History
NeoGenomics first received state and national-level laboratory certifications in 2002. Three years later in 2005, the company developed a technical-only service model using FISH.
In 2013, the company launched its sequencing platform and was listed on the Nasdaq Stock Market as NEO. In 2014, NeoGenomics launched molecular tests including BTK and CALR mutation analysis.
In 2015, NeoGenomics acquired Clarient, Inc. and its subsidiary company, Clarient Diagnostic Services, Inc., a national cancer diagnostics laboratory with capabilities in immunohistochemistry for solid tumor cancers from GE Healthcare. Clarient is headquartered in Aliso Viejo, California; with an ancillary laboratory in Houston, Texas.
In November 2017, NeoGenomics established their first headquarters outside the United States in Rolle, Switzerland.
In September 2024, the District Court for the Middle District of North Carolina entered a permanent injunction against NeoGenomics’ accused RaDaR assay, which was preliminarily enjoined in December 2023.
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
行业板块Health Care
行业Health Care
员工2500
国家US
10年表现 收入、净利润、利润率和每股收益趋势
收入$727M2016-12-31 → 2025-12-31
自由现金流$-22M2017-12-31 → 2025-12-31
净利率-6.8%2019-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | NEO | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E | -77.95年均值 ≈-73.2 | ≈-73.2 | · | · | |
| P/S (TTM) | 3.15年均值 ≈3.8 | ≈3.8 | 1.1 | 估值过高 | |
| 市净率 (MRQ) | 3.05年均值 ≈2.2 | ≈2.2 | 2.4 | 公允价值 | |
| EV / EBITDA (企业价值 / EBITDA) | -22.2 | · | · | · | |
| 股价/自由现金流 (TTM) | -321.25年均值 ≈-50.3 | ≈-50.3 | · | · | |
| 市现率 (TTM) | 107.25年均值 ≈-125.0 | ≈-125.0 | 13.5 | 估值过高 | |
| EV / Revenue (市值/营收) | 3.5 | · | · | · | |
| EV / FCF (市值/自由现金流) | -118.3 | · | · | · | |
| 市净率（有形资产） (MRQ) | 4.65年均值 ≈40.2 | ≈40.2 | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | NEO | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 毛利率 (TTM) | 43.9%5年均值 ≈40.8% | ≈40.8% | 32.6% | 顶尖 | |
| 营业利润率 (TTM) | -8.9%5年均值 ≈-20.7% | ≈-20.7% | 4.0% | 弱 | |
| EBITDA Margin (息税折旧摊销前利润率) | -15.9%5年均值 ≈-20.7% | ≈-20.7% | 4.5% | 弱 | |
| 税前利润率 (TTM) | -7.1%5年均值 ≈-15.6% | ≈-15.6% | 3.3% | 弱 | |
| 净利润率 (TTM) | -6.8%5年均值 ≈-14.3% | ≈-14.3% | 2.4% | 弱 | |
| ROA | -7.2%5年均值 ≈-5.1% | ≈-5.1% | 1.8% | 弱 | |
| ROE | -12.8%5年均值 ≈-9.2% | ≈-9.2% | 3.3% | 弱 | |
| ROIC | -9.6%5年均值 ≈-9.3% | ≈-9.3% | 5.0% | 弱 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | NEO | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 负债/股东权益比率 (MRQ) | 0.5 | · | 0.3 | 高负债 | |
| 流动比率 (MRQ) | 3.65年均值 ≈5.4 | ≈5.4 | 1.5 | 流动性强 | |
| Quick Ratio (速动比率) | 3.65年均值 ≈3.9 | ≈3.9 | 1.2 | 流动性强 | |
| 长期负债/股东权益 (MRQ) | 0.5 | · | 0.4 | 高负债 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | NEO | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | 10.1%5年均值 ≈10.4% | ≈10.4% | · | · | |
| Revenue CAGR 3Y (营收3年复合年增长率) | 12.6%5年均值 ≈11.2% | ≈11.2% | · | · | |
| Revenue CAGR 5Y (营收5年复合年增长率) | 10.3% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | NEO | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 0.55年均值 ≈0.4 | ≈0.4 | 1.6 | 弱 | |
| Inventory Turnover (库存周转率) | 14.95年均值 ≈13.7 | ≈13.7 | · | · | |
| Receivables Turnover (应收账款周转率) | 4.75年均值 ≈4.6 | ≈4.6 | 8.4 | 弱 | |
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$290.9K | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
55.4%
下次报告
十月 26, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 七月 27, 2026 | $0.05 | $0.03 | 51.1% |
| 2026年3月31日 | $0.01 | $0.01 | — | |
| 2025年12月31日 | $0.06 | $0.04 | 53.5% | |
| 2025年9月30日 | $0.03 | $0.02 | 40.8% | |
| 2025年6月30日 | $0.03 | $0.02 | 31.6% | |
| 2025年3月31日 | $0.00 | $-0.01 | 100.0% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $727M | $661M | $592M | $510M | $484M | $444M | $409M | $277M | $240M | $232M | $5M | $5M | |
| Cost of Revenue | $413M | $370M | $347M | $322M | $297M | $259M | $212M | $149M | $138M | $134M | $56M | $46M | |
| Gross Profit | $314M | $290M | $245M | $188M | $187M | $186M | $197M | $127M | $102M | $98M | $44M | $41M | |
| R&D Expense | $37M | $31M | $27M | $30M | $22M | $8M | $8M | $3M | $4M | $5M | $4M | $3M | |
| SG&A Expense | $273M | $260M | $243M | $243M | $221M | $144M | $128M | $85M | $70M | $64M | $34M | $24M | |
| Operating Expenses | $430M | $382M | $352M | $346M | $306M | $200M | $184M | $117M | $99M | $96M | $49M | $38M | |
| Operating Income | $-116M | $-92M | $-108M | $-158M | $-119M | $-14M | $13M | $10M | $3M | $2M | $-6M | $2M | |
| Interest Expense | · | · | $7M | $8M | $8M | $7M | $4M | $6M | $6M | · | $854.0K | $985.0K | |
| Interest Income | $9M | $18M | $17M | $6M | $3M | · | · | · | · | · | · | · | |
| Other Non-op | $296.0K | $-379.0K | $644.0K | $-213.0K | $-499.0K | $8M | $-5M | $14.0K | $-12.0K | $0 | $2M | $56.0K | |
| Pretax Income | $-110M | $-81M | $-97M | $-159M | $-15M | $-14M | $4M | $4M | $-3M | $-8M | $-4M | $1M | |
| Income Tax | $-2M | $-2M | $-9M | $-15M | $-7M | $-18M | $-4M | $1M | $-2M | $-2M | $-2M | $157.0K | |
| Net Income | $-108M | $-79M | $-88M | $-144M | $-8M | $4M | $8M | $3M | $-396.0K | $-6M | $-3M | $1M | |
| EPS (Basic) | · | · | · | · | · | · | · | · | · | · | $-0.04 | $0.02 | |
| EPS (Diluted) | · | · | · | · | · | · | · | · | · | · | $-0.04 | $0.02 | |
| Shares (Basic) | 128,101,000 | 126,658,000 | 125,502,000 | 124,217,000 | 119,962,000 | 108,579,000 | 100,470,000 | 85,618,000 | 79,426,000 | 77,542,000 | 60,526,000 | 53,483,000 | |
| Shares (Diluted) | 128,101,000 | 126,658,000 | 125,502,000 | 124,217,000 | 119,962,000 | 111,794,000 | 103,615,000 | 91,568,000 | 79,426,000 | 77,542,000 | 60,526,000 | 56,016,000 | |
| EBITDA | $-116M | $-92M | $-108M | $-158M | $-119M | $-14M | $13M | · | $2M | · | $-6M | · |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $160M | $367M | $342M | $263M | $317M | $229M | $173M | $10M | $13M | $13M | $23M | $34M | |
| Receivables | $159M | $151M | $131M | $120M | $112M | $107M | $94M | $77M | $60M | $56M | $49M | $20M | |
| Inventory | $29M | $27M | $24M | $24M | $23M | $30M | $14M | $9M | $7M | $6M | $5M | $3M | |
| Prepaid Expense | $21M | $20M | $18M | $15M | $12M | $12M | $6M | $8M | $5M | $5M | $5M | $1M | |
| Other Current Assets | $7M | $12M | $8M | $8M | $8M | $5M | $3M | $561.0K | $1M | · | · | · | |
| Current Assets | $376M | $596M | $597M | $605M | $682M | $449M | $291M | $104M | $86M | $79M | $82M | $59M | |
| PP&E (Net) | $85M | $94M | $92M | $102M | $109M | $86M | $64M | $61M | $37M | $34M | $35M | $15M | |
| PP&E (Gross) | $294M | $284M | $250M | $234M | $219M | $179M | $133M | $111M | $77M | $61M | $61M | $35M | |
| Accum. Depreciation | $209M | $190M | $158M | $132M | $110M | $93M | $69M | $50M | $41M | $27M | $27M | $20M | |
| Goodwill | $524M | $523M | $523M | $523M | $527M | $211M | $199M | $198M | $147M | $147M | $147M | $3M | |
| Intangibles | $287M | $340M | $373M | $408M | $442M | $121M | $127M | $140M | $74M | $77M | $88M | $4M | |
| Other Non-current Assets | $9M | $6M | $5M | $5M | $7M | $5M | $3M | $3M | $891.0K | $174.0K | $129.0K | $141.0K | |
| Total Assets | $1.36B | $1.64B | $1.68B | $1.74B | $1.87B | $988M | $710M | $505M | $344M | $337M | $351M | $81M | |
| Accounts Payable | $23M | $22M | $20M | $21M | $18M | $25M | $20M | $18M | $10M | $17M | $12M | $6M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Liabilities | $88M | $301M | $96M | $90M | $87M | $73M | $64M | $61M | $36M | $38M | $40M | $15M | |
| Capital Leases | $63M | $61M | $68M | $69M | $72M | $42M | $24M | $5M | $5M | $5M | $5M | $5M | |
| Deferred Tax | $18M | $22M | $24M | $35M | $55M | $5M | $16M | $22M | $7M | · | $16M | $821.0K | |
| Other Non-current Liabilities | $12M | $12M | $13M | $13M | $14M | $4M | $4M | $3M | $283.0K | · | · | · | |
| Total Liabilities | $523M | $736M | $740M | $742M | $762M | $294M | $202M | $185M | $140M | $151M | $113M | $21M | |
| Long-term Debt | $342M | $541M | $538M | · | · | · | · | $102M | $97M | $98M | $55M | · | |
| Total Debt | $342M | $541M | · | · | · | $0 | · | · | $95M | · | $53M | · | |
| Common Stock | · | · | · | · | · | · | · | · | · | · | · | $60.0K | |
| Retained Earnings | $-434M | $-326M | $-247M | $-159M | $-15M | $-7M | $-11M | $-19M | $-58M | $-52M | $-22M | $-19M | |
| Treasury Stock | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| AOCI | $4.0K | $-206.0K | $-2M | $-4M | $-638.0K | $10.0K | $-2M | $-579.0K | $274.0K | · | · | · | |
| Stockholders' Equity | $837M | $902M | $942M | $998M | $1.11B | $694M | $507M | $320M | $172M | $162M | $209M | $60M | |
| Liabilities + Equity | $1.36B | $1.64B | $1.68B | $1.74B | $1.87B | $988M | $710M | $505M | $344M | $337M | $351M | $81M | |
| Shares Outstanding | 128,989,152 | 128,145,333 | 127,369,142 | 126,913,992 | 124,107,500 | 112,075,474 | 104,781,236 | 94,465,440 | 80,462,574 | 78,571,158 | 75,820,307 | 60,242,818 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | $26M | $20M | $16M | $16M | $16M | $7M | $5M | |
| Stock-based Comp | $41M | $33M | $25M | $25M | $22M | $10M | $10M | $7M | $6M | $5M | $3M | $641.0K | |
| Deferred Tax | $-3M | $-3M | $-10M | $-15M | $-7M | $-18M | $-4M | $2M | $-2M | $-2M | $-2M | · | |
| Amort. of Intangibles | $32M | $33M | $35M | $34M | $23M | $10M | $10M | $6M | $7M | $7M | $412.0K | $295.0K | |
| Restructuring | $0 | $7M | $11M | $5M | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $5M | $7M | $-2M | $-66M | $-27M | $1M | $23M | $45M | $18M | $21M | $6M | $9M | |
| CapEx | $27M | $41M | $29M | $31M | $64M | $29M | $20M | $14M | $14M | $8M | $2M | $4M | |
| Investing Cash Flow | $-12M | $13M | $77M | $517.0K | $-632M | $-159M | $-20M | $-140M | $-14M | · | · | · | |
| Stock Issued | $962.0K | $5M | $5M | $13M | $15M | $20M | $11M | $9M | $3M | · | · | $34M | |
| Net Stock Activity | $962.0K | $5M | $5M | $13M | $15M | $20M | $11M | · | · | · | · | · | |
| Financing Cash Flow | $-200M | $5M | $5M | $12M | $725M | $236M | $159M | $92M | $-4M | · | · | · | |
| Net Change in Cash | · | · | · | · | · | $78M | $163M | $-3M | $296.0K | $-11M | $-10M | $29M | |
| Taxes Paid | $515.0K | $207.0K | $175.0K | $180.0K | $148.0K | $246.0K | $319.0K | $-31.0K | $284.0K | $290.0K | · | · | |
| Free Cash Flow | $-22M | $-34M | $-31M | $-97M | $-91M | $-28M | $3M | · | $4M | · | $4M | · | |
| Levered FCF | · | · | $-37M | $-98M | $-94M | $-26M | $-5M | · | · | · | $4M | · |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 43.2% | 43.9% | 41.3% | 36.9% | 38.6% | 41.8% | 48.1% | · | · | · | 875.1% | · | |
| Operating Margin | -15.9% | -13.9% | -18.2% | -30.9% | -24.5% | -3.1% | 3.2% | · | · | · | -112.7% | · | |
| Net Margin | -14.8% | -11.9% | -14.9% | -28.3% | -1.7% | 0.94% | 2.0% | · | · | · | -50.7% | · | |
| Pretax Margin | -15.2% | -12.2% | -16.4% | -31.3% | -3.1% | -3.2% | 0.89% | · | · | · | -89.8% | · | |
| EBITDA Margin | -15.9% | -13.9% | -18.2% | -30.9% | -24.5% | -3.1% | 3.2% | · | · | · | -112.7% | · | |
| ROA | -7.2% | -4.7% | -5.1% | -8.0% | -0.58% | 0.49% | 1.3% | · | -0.25% | · | -1.1% | · | |
| ROE | -12.8% | -8.7% | -9.3% | -14.3% | -0.74% | 0.61% | 1.6% | · | -0.50% | · | -1.9% | · | |
| ROIC | -9.6% | -6.2% | -10.4% | -14.3% | -5.9% | 0.60% | 5.6% | · | 0.21% | · | -1.2% | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.3 | 2.0 | 6.2 | 6.7 | 7.8 | 6.1 | 4.5 | · | 2.4 | · | 2.5 | · | |
| Quick Ratio | 3.6 | 1.7 | 4.9 | 4.3 | 4.9 | 4.6 | 4.2 | · | 2.1 | · | 1.8 | · | |
| Debt / Equity | 0.4 | 0.6 | · | · | · | 0.0 | · | · | 0.5 | · | 0.3 | · | |
| LT Debt / Equity | 0.4 | 0.4 | · | · | · | · | · | · | 0.5 | · | 0.2 | · | |
| Interest Coverage | · | · | -15.6 | -104.7 | -23.4 | -2.0 | 3.5 | · | · | · | -6.6 | · |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.4 | 0.3 | 0.3 | 0.3 | 0.5 | 0.7 | · | · | · | 0.0 | · | |
| Inventory Turnover | 14.9 | 14.6 | 14.3 | 13.5 | 11.2 | 11.8 | 18.4 | · | 20.1 | · | 14.5 | · | |
| Receivables Turnover | 4.7 | 4.7 | 4.7 | 4.4 | 4.4 | 4.4 | 4.8 | · | · | · | 0.1 | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.53 | $7.08 | $7.42 | $8.04 | $9.89 | $6.63 | $5.37 | · | $2.15 | · | $2.76 | · | |
| Revenue / Share | $5.68 | $5.22 | $4.71 | $4.10 | $4.04 | $3.98 | $3.95 | · | · | · | $0.08 | · | |
| Cash Flow / Share | $0.04 | $0.06 | $-0.02 | $-0.53 | $-0.22 | $0.01 | $0.23 | · | $0.23 | · | $0.11 | · | |
| Cash / Share | $1.25 | $2.88 | $2.70 | $2.12 | $2.83 | $2.18 | $1.83 | · | $0.16 | · | $0.31 | · | |
| EPS (TTM) | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.04 | $0.02 |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 10.1% | 11.7% | 16.1% | 5.2% | 9.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 12.6% | 10.9% | 10.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 10.3% | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $727M | $661M | $592M | $510M | $484M | $444M | $409M | $277M | $240M | $232M | $5M | $5M | |
| Net Income TTM | $-108M | $-79M | $-88M | $-144M | $-8M | $4M | $8M | $3M | $-396.0K | $-6M | $-3M | $1M | |
| Market Cap | $1.51B | $2.10B | $2.05B | $1.15B | $3.82B | $5.64B | $2.76B | · | $713M | · | $597M | · | |
| Enterprise Value | $1.69B | $2.27B | · | · | · | $5.41B | · | · | $795M | · | $626M | · | |
| P/E | -49.0 | -68.7 | -67.4 | -38.5 | -142.2 | -224.3 | -121.9 | -52.5 | -36.9 | -35.7 | -196.8 | 208.5 | |
| P/S | 2.1 | 3.2 | 3.5 | 2.2 | 7.9 | 12.7 | 6.8 | · | 3.0 | · | 119.3 | · | |
| P/B | 1.8 | 2.3 | 2.2 | 1.1 | 3.5 | 8.1 | 5.4 | · | 4.1 | · | 2.8 | · | |
| P / Tangible Book | 58.7 | 52.6 | 45.0 | 17.1 | 27.5 | 15.6 | · | · | · | · | · | · | |
| P / Cash Flow | 288.1 | 298.9 | -1051.4 | -17.4 | -143.1 | 3864.0 | 118.2 | · | 39.5 | · | 93.3 | · | |
| P / FCF | -69.2 | -61.7 | -66.9 | -11.8 | -42.1 | -204.1 | 827.3 | · | 164.0 | · | 142.8 | · | |
| EV / EBITDA | -14.6 | -24.7 | · | · | · | -386.8 | · | · | 342.1 | · | -111.1 | · | |
| EV / FCF | -77.6 | -66.8 | · | · | · | -195.9 | · | · | 182.9 | · | 149.9 | · | |
| EV / Revenue | 2.3 | 3.4 | · | · | · | 12.2 | · | · | 3.3 | · | 125.2 | · | |
| Earnings Yield | -2.0% | -1.5% | -1.5% | -2.6% | -0.70% | -0.45% | -0.82% | -1.9% | -2.7% | -2.8% | -0.51% | 0.48% |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $202M | $187M | $190M | $188M | $181M | $168M | $172M | $168M | $165M | $156M | $156M | $152M | $147M | $137M | $139M | $129M | |
| Cost of Revenue | $110M | $106M | $107M | $107M | $104M | $95M | $95M | $93M | $92M | $91M | $88M | $90M | $87M | $82M | $82M | $80M | |
| Gross Profit | $92M | $81M | $83M | $80M | $77M | $73M | $77M | $75M | $72M | $65M | $68M | $62M | $60M | $55M | $57M | $49M | |
| R&D Expense | $11M | $10M | $9M | $9M | $9M | $10M | $8M | $8M | $8M | $8M | $7M | $5M | $8M | $7M | $7M | $7M | |
| SG&A Expense | $64M | $66M | $64M | $70M | $72M | $68M | $64M | $67M | $63M | $66M | $60M | $61M | $60M | $62M | $55M | $64M | |
| Operating Expenses | $102M | $99M | $97M | $107M | $125M | $101M | $96M | $96M | $94M | $96M | $86M | $87M | $90M | $90M | $83M | $88M | |
| Operating Income | $-10M | $-18M | $-13M | $-27M | $-48M | $-28M | $-18M | $-21M | $-22M | $-31M | $-19M | $-24M | $-30M | $-35M | $-26M | $-40M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $2M | · | $-3M | $-3M | $2M | · | $139.0K | |
| Interest Income | $1M | $1M | $2M | $2M | $2M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $4M | $3M | · | · | |
| Other Non-op | $-17.0K | $-12.0K | $84.0K | $-335.0K | $482.0K | $65.0K | $-431.0K | $317.0K | $-2.0K | $-263.0K | $124.0K | $-96.0K | $730.0K | $-114.0K | $-1.0K | $25.0K | |
| Pretax Income | $2M | $-18M | $-12M | $-26M | $-46M | $-26M | $-16M | $-18M | $-19M | $-28M | $-15M | $-21M | $-27M | $-34M | $-26M | $-40M | |
| Income Tax | $-412.0K | $-472.0K | $-3M | $740.0K | $-724.0K | $266.0K | $-804.0K | $-150.0K | $-375.0K | $-620.0K | $-960.0K | $-3M | $-2M | $-3M | $-3M | $-3M | |
| Net Income | $2M | $-17M | $-10M | $-27M | $-45M | $-26M | $-15M | $-18M | $-19M | $-27M | $-14M | $-19M | $-24M | $-31M | $-23M | $-37M | |
| Shares (Basic) | 129,628,000 | 129,166,000 | · | 128,415,000 | 127,949,000 | 127,376,000 | · | 126,953,000 | 126,405,000 | 126,111,000 | · | 125,687,000 | 125,356,000 | 125,026,000 | · | 124,425,000 | |
| Shares (Diluted) | 130,831,000 | 129,166,000 | · | 128,415,000 | 127,949,000 | 127,376,000 | · | 126,953,000 | 126,405,000 | 126,111,000 | · | 125,687,000 | 125,356,000 | 125,026,000 | · | 124,425,000 | |
| EBITDA | $-10M | $-18M | · | $-27M | $-48M | $-28M | · | $-21M | $-22M | $-31M | · | $-24M | $-30M | $-35M | · | $-40M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $146M | $146M | $160M | $164M | $155M | $346M | $367M | $362M | $355M | $332M | · | $306M | $289M | $276M | · | $266M | |
| Receivables | $175M | $167M | $159M | $155M | $153M | $151M | $151M | $151M | $147M | $140M | · | $133M | $125M | $119M | · | $112M | |
| Inventory | $27M | $30M | $29M | $28M | $34M | $30M | $27M | $24M | $23M | $20M | · | $24M | $25M | $24M | · | $24M | |
| Prepaid Expense | $24M | $24M | $21M | $22M | $23M | $23M | $20M | $18M | $17M | $19M | · | $19M | $17M | $16M | · | $17M | |
| Other Current Assets | $10M | $7M | $7M | $11M | $10M | $12M | $12M | $8M | $9M | $9M | · | $9M | $8M | $8M | · | $8M | |
| Current Assets | $381M | $374M | $376M | $382M | $393M | $574M | $596M | $590M | $584M | $574M | · | $587M | $585M | $585M | · | $603M | |
| PP&E (Net) | $81M | $84M | $85M | $85M | $85M | $90M | $94M | $93M | $92M | $88M | · | $95M | $100M | $103M | · | $107M | |
| PP&E (Gross) | · | · | $294M | · | · | · | $284M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $223M | $216M | $209M | $209M | $201M | $199M | $190M | $181M | $176M | $168M | · | $155M | $147M | $139M | · | $125M | |
| Goodwill | $524M | $524M | $524M | $524M | $524M | $523M | $523M | $523M | $523M | $523M | $523M | $523M | $523M | $523M | · | $523M | |
| Intangibles | $271M | $279M | $287M | $294M | $302M | $331M | $340M | $348M | $356M | $365M | · | $382M | $391M | $399M | · | $417M | |
| Other Non-current Assets | $9M | $10M | $9M | $8M | $7M | $6M | $6M | $6M | $4M | $4M | · | $5M | $5M | $5M | · | $7M | |
| Total Assets | $1.35B | $1.35B | $1.36B | $1.37B | $1.39B | $1.60B | $1.64B | $1.64B | $1.64B | $1.64B | · | $1.68B | $1.70B | $1.71B | · | $1.76B | |
| Accounts Payable | $21M | $26M | $23M | $23M | $27M | $16M | $22M | $17M | $17M | $18M | · | $17M | $18M | $23M | · | $14M | |
| Current Liabilities | $106M | $85M | $88M | $98M | $100M | $280M | $301M | $296M | $290M | $77M | · | $93M | $95M | $87M | · | $85M | |
| Capital Leases | $65M | $61M | $63M | $64M | $67M | $60M | $61M | $62M | $63M | $65M | · | $62M | $65M | $67M | · | $70M | |
| Deferred Tax | $17M | $17M | $18M | $21M | $20M | $21M | $22M | $23M | $23M | $23M | · | $25M | $29M | $32M | · | $38M | |
| Other Non-current Liabilities | $862.0K | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $13M | · | $13M | $13M | $13M | · | $14M | |
| Total Liabilities | $567M | $518M | $523M | $536M | $540M | $713M | $736M | $733M | $727M | $717M | · | $731M | $739M | $735M | · | $743M | |
| Long-term Debt | · | · | $342M | · | · | · | $541M | · | · | · | · | · | · | · | · | · | |
| Total Debt | $374M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Retained Earnings | $-449M | $-451M | $-434M | $-424M | $-397M | $-352M | $-326M | $-310M | $-293M | $-274M | · | $-233M | $-214M | $-190M | · | $-136M | |
| Treasury Stock | $25M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| AOCI | $4.0K | $4.0K | $4.0K | $71.0K | $29.0K | $-56.0K | $-206.0K | $-643.0K | $-1M | $-1M | · | $-2M | $-3M | $-3M | · | $-5M | |
| Stockholders' Equity | $786M | $829M | $837M | $838M | $854M | $888M | $902M | $908M | $916M | $923M | $942M | $947M | $956M | $974M | $998M | $1.01B | |
| Liabilities + Equity | $1.35B | $1.35B | $1.36B | $1.37B | $1.39B | $1.60B | $1.64B | $1.64B | $1.64B | $1.64B | · | $1.68B | $1.70B | $1.71B | · | $1.76B | |
| Shares Outstanding | 127,917,946 | 129,653,642 | 128,145,333 | 128,885,101 | 128,681,713 | 128,356,327 | 128,145,333 | 128,061,944 | 127,851,113 | 127,434,786 | 127,369,142 | 127,261,476 | 127,144,418 | 127,200,491 | 126,913,992 | 126,562,037 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $8M | $10M | $8M | $10M | $12M | $11M | $8M | $0 | $9M | $8M | $7M | $0 | $6M | $5M | $5M | $4M | |
| Amort. of Intangibles | $8M | $8M | $8M | $8M | $8M | $8M | $8M | $8M | $8M | $8M | $9M | $9M | $9M | $9M | $9M | $8M | |
| Restructuring | · | · | · | · | · | · | · | · | · | $2M | $1M | $2M | $3M | $5M | · | $0 | |
| Operating Cash Flow | $20M | $-8M | $1M | $9M | $20M | $-25M | $10M | $9M | $14M | $-26M | $18M | $-5M | $-2M | $-13M | $-4M | $-16M | |
| CapEx | $8M | $5M | $8M | $8M | $6M | $4M | $12M | $11M | $13M | $6M | $7M | $4M | $7M | $10M | $5M | $8M | |
| Investing Cash Flow | $-8M | $-5M | $-6M | $-277.0K | $-9M | $4M | $-5M | $-4M | $7M | $15M | $17M | $21M | $15M | $24M | $-1M | $-4M | |
| Stock Issued | $2M | $-338.0K | $431.0K | $765.0K | $-1M | $949.0K | $687.0K | $1M | $2M | $816.0K | $1M | $2M | $93.0K | $1M | $2M | $3M | |
| Net Stock Activity | · | $-338.0K | · | · | · | $949.0K | · | · | · | $816.0K | · | · | · | $1M | · | · | |
| Financing Cash Flow | $-12M | $-338.0K | $431.0K | $765.0K | $-202M | $949.0K | $687.0K | $1M | $2M | $816.0K | $1M | $2M | $64.0K | $1M | $2M | $3M | |
| Net Change in Cash | · | · | · | $9M | · | · | · | $7M | $23M | $-11M | · | $17M | $13M | $12M | · | $-18M | |
| Taxes Paid | $711.0K | $0 | $57.0K | $0 | $458.0K | $0 | $-112.0K | $143.0K | $87.0K | $89.0K | $0 | $0 | $175.0K | $0 | $25.0K | $26.0K | |
| Free Cash Flow | · | $-13M | · | · | · | $-30M | · | · | · | $-32M | · | · | · | $-23M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-33M | · | · | · | · | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 45.6% | 43.3% | · | 42.8% | 42.6% | 43.6% | · | 44.6% | 44.1% | 41.9% | · | 41.0% | 40.8% | 40.0% | · | 38.0% | |
| Operating Margin | -4.9% | -9.8% | · | -14.4% | -26.3% | -16.6% | · | -12.6% | -13.3% | -19.6% | · | -15.9% | -20.3% | -25.6% | · | -30.7% | |
| Net Margin | 1.1% | -9.2% | · | -14.4% | -24.9% | -15.4% | · | -10.5% | -11.3% | -17.3% | · | -12.2% | -16.6% | -22.4% | · | -28.6% | |
| Pretax Margin | 0.91% | -9.4% | · | -14.1% | -25.3% | -15.3% | · | -10.6% | -11.6% | -17.7% | · | -14.1% | -18.1% | -24.6% | · | -30.8% | |
| EBITDA Margin | -4.9% | -9.8% | · | -14.4% | -26.3% | -16.6% | · | -12.6% | -13.3% | -19.6% | · | -15.9% | -20.3% | -25.6% | · | -30.7% | |
| ROA | 0.16% | -1.2% | · | -1.8% | -3.0% | -1.6% | · | -1.1% | -1.1% | -1.6% | · | -1.1% | -1.4% | -1.7% | · | -2.0% | |
| ROE | 0.27% | -2.0% | · | -3.1% | -5.1% | -2.9% | · | -1.9% | -2.0% | -2.9% | · | -1.9% | -2.4% | -3.0% | · | -3.4% | |
| ROIC | -1.0% | -2.1% | · | -3.3% | -5.5% | -3.2% | · | -2.3% | -2.4% | -3.2% | · | -2.2% | -2.9% | -3.3% | · | -3.6% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | 4.4 | · | 3.9 | 3.9 | 2.1 | · | 2.0 | 2.0 | 7.5 | · | 6.3 | 6.2 | 6.8 | · | 7.1 | |
| Quick Ratio | 3.0 | 3.7 | · | 3.3 | 3.1 | 1.8 | · | 1.7 | 1.7 | 6.2 | · | 4.7 | 4.4 | 4.6 | · | 4.4 | |
| Debt / Equity | 0.5 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -18.1 | · | 8.5 | 11.8 | · | · | -284.2 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 3.6 | 3.6 | · | 4.1 | 3.6 | 3.8 | · | 3.8 | 3.8 | 4.1 | · | 3.7 | 3.7 | 3.4 | · | 3.5 | |
| Receivables Turnover | 1.2 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.2 |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.14 | $6.39 | · | $6.50 | $6.64 | $6.92 | · | $7.09 | $7.16 | $7.25 | · | $7.44 | $7.52 | $7.66 | · | $8.00 | |
| Revenue / Share | $1.54 | $1.45 | · | $1.46 | $1.42 | $1.32 | · | $1.32 | $1.30 | $1.24 | · | $1.21 | $1.17 | $1.10 | · | $1.03 | |
| Cash Flow / Share | · | $-0.06 | · | · | · | $-0.20 | · | · | · | $-0.21 | · | · | · | $-0.10 | · | · | |
| Cash / Share | $1.14 | $1.13 | · | $1.27 | $1.20 | $2.70 | · | $2.83 | $2.78 | $2.60 | · | $2.41 | $2.27 | $2.17 | · | $2.10 | |
| EPS (TTM) | $-0.24 | $-0.24 | · | $-0.24 | $-0.24 | $-0.24 | · | $-0.24 | $-0.24 | $-0.24 | · | $-0.24 | $-0.24 | $-0.24 | · | $-0.24 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $766M | $746M | · | $709M | $689M | $672M | · | $644M | $628M | $611M | · | $575M | $552M | $530M | · | $497M | |
| Net Income TTM | $-52M | $-99M | · | $-113M | $-104M | $-78M | · | $-78M | $-79M | $-84M | · | $-96M | $-115M | $-126M | · | $-163M | |
| Market Cap | $1.87B | $962M | · | $995M | $941M | $1.22B | · | $1.89B | $1.77B | $2.00B | · | $1.57B | $2.04B | $2.21B | · | $1.09B | |
| Enterprise Value | $2.10B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -60.8 | -30.9 | · | -32.2 | -30.5 | -39.5 | · | -61.5 | -57.8 | -65.5 | · | -51.2 | -67.0 | -72.5 | · | -35.9 | |
| P/S | 2.4 | 1.3 | · | 1.4 | 1.4 | 1.8 | · | 2.9 | 2.8 | 3.3 | · | 2.7 | 3.7 | 4.2 | · | 2.2 | |
| P/B | 2.4 | 1.2 | · | 1.2 | 1.1 | 1.4 | · | 2.1 | 1.9 | 2.2 | · | 1.7 | 2.1 | 2.3 | · | 1.1 | |
| P / Tangible Book | · | 37.2 | · | 50.3 | 33.5 | 35.6 | · | 50.5 | 48.3 | 55.8 | · | 36.6 | 47.8 | 42.4 | · | 14.9 | |
| P / Cash Flow | · | -118.2 | · | · | · | -48.1 | · | · | · | -77.3 | · | · | · | -174.5 | · | · | |
| EV / Revenue | 2.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -1.6% | -3.2% | · | -3.1% | -3.3% | -2.5% | · | -1.6% | -1.7% | -1.5% | · | -1.9% | -1.5% | -1.4% | · | -2.8% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $727M | $661M | $592M | $510M | $484M |
| 毛利率 % | 43.2% | 43.9% | 41.3% | 36.9% | 38.6% |
| 营业利润率 % | -15.9% | -13.9% | -18.2% | -30.9% | -24.5% |
| 净收入 | $-108M | $-79M | $-88M | $-144M | $-8M |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 负债/股东权益比率 | 0.4 | 0.6 | · | · | · |
| 流动比率 | 4.3 | 2.0 | 6.2 | 6.7 | 7.8 |
| 速动比率 | 3.6 | 1.7 | 4.9 | 4.3 | 4.9 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $-22M | $-34M | $-31M | $-97M | $-91M |
机构持有人 (13F) 296 家申报者 · $2.4B 总计 · 截至 2026年9月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
296
持有价值
$2.4B
新仓位
58
已退出持仓
38
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 58 (+9 与上一季度对比) | 38 (+2 与上一季度对比) | 100 (+22 与上一季度对比) | 61 (-22 与上一季度对比) | +19.6M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| BlackRock, Inc. | $304469400 | 20868362 | 12.94% | 股份 |
| First Light Asset Management, LLC | $179158241 | 12279523 | 7.61% | 股份 |
| VANGUARD GROUP INC | $162621455 | 13828355 | 6.91% | 股份 |
| FIRST TRUST ADVISORS LP | $147552477 | 10113261 | 6.27% | 股份 |
| Greenhouse Funds LLLP | $125097724 | 8574210 | 5.32% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $117615272 | 8061362 | 5.00% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $84082418 | 5763017 | 3.57% | 股份 |
| STATE STREET CORP | $78257609 | 5363784 | 3.33% | 股份 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $73501000 | 5037787 | 3.12% | 股份 |
| BRAIDWELL LP | $71756567 | 4918202 | 3.05% | 股份 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $61886083 | 4342883 | 2.63% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $50558727 | 3465300 | 2.15% | 买入期权 |
| GEODE CAPITAL MANAGEMENT, LLC | $50025999 | 3428123 | 2.13% | 股份 |
| MILLENNIUM MANAGEMENT LLC | $44930518 | 3079542 | 1.91% | 股份 |
| TORONTO DOMINION BANK | $43770000 | 3000000 | 1.86% | 买入期权 |
| LOOMIS SAYLES & CO L P | $37025291 | 2537717 | 1.57% | 股份 |
| Driehaus Capital Management LLC | $36604049 | 2508845 | 1.56% | 股份 |
| BANK OF AMERICA CORP /DE/ | $35546038 | 2436329 | 1.51% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $35003708 | 2399411 | 1.49% | 股份 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $34896129 | 2391784 | 1.48% | 股份 |
| AMERICAN CAPITAL MANAGEMENT INC | $32648145 | 2237707 | 1.39% | 股份 |
| UBS Group AG | $32581659 | 2233150 | 1.38% | 买入期权 |
| D. E. Shaw & Co., Inc. | $32021519 | 2194758 | 1.36% | 股份 |
| SAMLYN CAPITAL, LLC | $31096207 | 2131337 | 1.32% | 股份 |
| Aberdeen Group plc | $28180950 | 1931525 | 1.20% | 股份 |
| MORGAN STANLEY | $27693709 | 1898128 | 1.18% | 股份 |
| GOLDMAN SACHS GROUP INC | $22859028 | 1566760 | 0.97% | 股份 |
| NORTHERN TRUST CORP | $22456651 | 1539181 | 0.95% | 股份 |
| GLENMEDE TRUST CO NA | $22141579 | 1517586 | 0.94% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $17689018 | 1212407 | 0.75% | 股份 |
| SEGALL BRYANT & HAMILL, LLC | $15850518 | 1086396 | 0.67% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $12685640 | 869475 | 0.54% | 股份 |
| AQR CAPITAL MANAGEMENT LLC | $12149312 | 832715 | 0.52% | 股份 |
| Glenmede Investment Management, LP | $12057018 | 1561790 | 0.51% | 股份 |
| Connor, Clark & Lunn Investment Management Ltd. | $11709890 | 802597 | 0.50% | 股份 |
| Bank of New York Mellon Corp | $10743609 | 736368 | 0.46% | 股份 |
| CITIGROUP INC | $9748716 | 668178 | 0.41% | 股份 |
| PRINCIPAL FINANCIAL GROUP INC | $9189162 | 629826 | 0.39% | 股份 |
| HighMark Wealth Management LLC | $8936871 | 612534 | 0.38% | 股份 |
| Invesco Ltd. | $8754555 | 600038 | 0.37% | 股份 |
| UBS Group AG | $8391672 | 575166 | 0.36% | 股份 |
| JPMORGAN CHASE & CO | $8363938 | 581091 | 0.36% | 股份 |
| JUPITER ASSET MANAGEMENT LTD | $7841935 | 537487 | 0.33% | 股份 |
| Public Sector Pension Investment Board | $6526545 | 447330 | 0.28% | 股份 |
| Trexquant Investment LP | $6358074 | 435783 | 0.27% | 股份 |
| Nuveen, LLC | $6172300 | 423050 | 0.26% | 股份 |
| Granite Investment Partners, LLC | $5181507 | 355141 | 0.22% | 股份 |
| AMERIPRISE FINANCIAL INC | $4625865 | 317057 | 0.20% | 股份 |
| RHUMBLINE ADVISERS | $4624054 | 316935 | 0.20% | 股份 |
| Legal & General Group Plc | $4317503 | 295922 | 0.18% | 股份 |
激进投资者及 5%+ 股东 1 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| IRS IDENTIFICATION NO. NeoGenomics, Inc. | 2007年4月12日 | · | 初始申报 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 52 位内幕人士 · 31 位高管 · 23 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Anthony P. Zook | Chief Executive Officer | 2026年4月1日 M | 133111 | 0 | 0 | $0 |
| Christopher M Smith | Chief Executive Officer | 2025年2月23日 M | 641585 | 0 | 0 | $0 |
| Mark Mallon | Chief Executive Officer | 2022年3月1日 A | 368051 | 0 | 0 | $0 |
| Jeffrey Scott Sherman | Chief Financial Officer | 2026年2月23日 M | 220009 | 0 | 0 | $0 |
| William Bonello | Chief Financial Officer | 2022年4月28日 M | 191548 | 0 | 0 | $0 |
| Sharon Virag | Chief Financial Officer | 2019年3月1日 A | 10944 | 0 | 0 | $0 |
| Vishal Sikri | President Advanced Diagnostics | 2024年2月23日 A | 127716 | 0 | 0 | $0 |
| David Sholehvar | President, Clinical Services | 2022年8月1日 A | 43216 | 0 | 0 | $0 |
| George Cardoza | President & COO, Lab Ops | 2022年3月2日 F | 244157 | 0 | 0 | $0 |
| Gina M Wallar | President, Pharma Services | 2022年3月1日 A | 33443 | 0 | 0 | $0 |
| Clive Morris | President of Inivata | 2021年12月30日 A | 41280 | 0 | 0 | $0 |
| Robert J. Shovlin | President, Clinical Services | 2021年5月25日 M | 150101 | 0 | 0 | $0 |
| Warren Stone | Pres & Chief Operating Officer | 2026年8月21日 M | 181078 | 0 | 1 | $-276600 |
| Alicia C Olivo | EVP, GC & Business Development | 2026年9月1日 F | 90875 | 0 | 2 | $-300172 |
| Greg D Aunan | Chief Accounting Officer | 2026年8月4日 S | 5153 | 0 | 1 | $-321400 |
| Melody Harris | Chf Ops Off, Pres, Informatics | 2025年2月23日 M | 109755 | 0 | 0 | $0 |
| Shashikant Kulkarni | Chief Scientific Officer | 2023年4月1日 F | 82673 | 0 | 0 | $0 |
| Cynthia J Dieter | Chief Accounting Officer | 2023年3月2日 F | 29765 | 0 | 0 | $0 |
| Douglas Matthew Brown | Chief Strategy Officer | 2022年4月1日 A | 158684 | 0 | 0 | $0 |
| Halley E Gilbert | Chief Legal Officer | 2022年3月1日 A | 147396 | 0 | 0 | $0 |
| Kathryn B Mckenzie | Chief Sustainability/Risk Ofcr | 2022年1月11日 M | 49361 | 0 | 0 | $0 |
| Jennifer Balliet | VP and Chief Culture Officer | 2021年12月30日 A | 48615 | 0 | 0 | $0 |
| Lawrence Martin Weiss | Chief Medical Officer | 2021年4月22日 M | 130847 | 0 | 0 | $0 |
| Denise E Pedulla | General Counsel | 2021年3月2日 A | 60643 | 0 | 0 | $0 |
| Steven G. Brodie | VP - Pharma Operations | 2018年10月22日 M | 45953 | 0 | 0 | $0 |
| Steven A Ross | CIO | 2018年5月10日 X | 4500 | 0 | 0 | $0 |
| Maher Albitar | Chief Medical Officer | 2017年5月25日 A | 60692 | 0 | 0 | $0 |
| Mark Alan Machulcz | Vice President of Operations | 2016年1月28日 A | · | 0 | 0 | $0 |
| Robert H. Horel | Vice President GM PathLogic | 2015年12月29日 X | 51218 | 0 | 0 | $0 |
| Robert P Gasparini | Chief Science Officer | 2014年5月22日 X | 8439 | 0 | 0 | $0 |
| Mark W Smits | Chief Commercial Officer | 2011年5月18日 M | 0 | 0 | 0 | $0 |
| Carolyn S Starrett | 董事 | 2026年6月23日 A | · | 0 | 0 | $0 |
| Lynn A. Tetrault | 董事 | 2026年6月15日 S | 86115 | 0 | 2 | $-118824 |
| Marjorie C Green | 董事 | 2026年6月1日 A | 22964 | 0 | 0 | $0 |
| Neil Gunn | 董事 | 2026年6月1日 A | 51177 | 0 | 0 | $0 |
| Michael Aaron Kelly | 董事 | 2026年6月1日 A | 67086 | 0 | 0 | $0 |
| David Brian Perez | 董事 | 2026年6月1日 A | 56967 | 0 | 0 | $0 |
| John P. Kenny | 董事 | 2026年6月1日 A | 5893 | 0 | 0 | $0 |
| Stephen M Kanovsky | 董事 | 2026年6月1日 A | 75421 | 0 | 0 | $0 |
| Felicia Williams | 董事 | 2026年6月1日 A | 30237 | 0 | 0 | $0 |
| Elizabeth Floegel | 董事 | 2025年6月1日 A | 23590 | 0 | 0 | $0 |
| Alison L. Hannah | 董事 | 2025年6月1日 M | 131023 | 0 | 0 | $0 |
| Bruce K Crowther | 董事 | 2023年8月10日 A | 65120 | 0 | 0 | $0 |
| Rachel A Stahler | 董事 | 2022年6月10日 A | 21335 | 0 | 0 | $0 |
| David Daly | 董事 | 2022年6月10日 A | 17179 | 0 | 0 | $0 |
| Kevin C Johnson | 董事 | 2021年12月22日 M | 37398 | 0 | 0 | $0 |
| Douglas M Van Oort | 董事 | 2021年8月1日 F | 2468797 | 0 | 0 | $0 |
| Steven C Jones | 董事 | 2021年1月7日 M | 90218 | 0 | 0 | $0 |
| Raymond R Hipp | 董事 | 2020年11月16日 S | 66800 | 0 | 0 | $0 |
| William J Robison | 董事 | 2017年5月25日 A | 183348 | 0 | 0 | $0 |
| Michael T Dent | 董事 | 2014年12月4日 S | 1384150 | 0 | 0 | $0 |
| Peter M Peterson | 董事 | 2012年6月5日 A | 34500 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 51 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| PSCH · Invesco Exchange-Traded Fund Trus... | 1.27% | 123482 SH | 2026年10月1日 | 每日 |
| PTH · Invesco Exchange-Traded Fund Trust | 1.23% | 246967 SH | 2026年10月1日 | 每日 |
| XSMO · Invesco Exchange-Traded Fund Trust | 0.84% | 1312803 SH | 2026年10月1日 | 每日 |
| FYC · First Trust Exchange-Traded Alpha... | 0.71% | 601468 NS | 2026年7月31日 | N-PORT |
| IHF · iShares Trust | 0.34% | 250331 SH | 2026年9月11日 | 每日 |
| FYX · First Trust Exchange-Traded Alpha... | 0.27% | 239159 NS | 2026年7月31日 | N-PORT |
| QVMS · Invesco Exchange-Traded Fund Trus... | 0.16% | 19929 SH | 2026年10月1日 | 每日 |
| NUSC · Nushares ETF Trust | 0.15% | 126293 NS | 2026年7月31日 | N-PORT |
| FAD · First Trust Exchange-Traded Alpha... | 0.14% | 54487 NS | 2026年7月31日 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.12% | 180254 SH | 2026年10月1日 | 每日 |
| VIOG · VANGUARD ADMIRAL FUNDS | 0.12% | 89895 SH | 2026年8月19日 | 每日 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.11% | 104297 SH | 2026年8月19日 | 每日 |
| VIOO · VANGUARD ADMIRAL FUNDS | 0.10% | 455144 SH | 2026年8月19日 | 每日 |
| ESML · iShares Trust | 0.09% | 146435 SH | 2026年9月11日 | 每日 |
| VIOV · VANGUARD ADMIRAL FUNDS | 0.09% | 116046 SH | 2026年8月19日 | 每日 |
| JPSE · J.P. Morgan Exchange-Traded Fund ... | 0.09% | 33444 NS | 2026年7月31日 | N-PORT |
| IWM · iShares Trust | 0.08% | 3367792 SH | 2026年9月11日 | 每日 |
| BBSC · J.P. Morgan Exchange-Traded Fund ... | 0.08% | 34215 NS | 2026年7月31日 | N-PORT |
| ISCG · iShares Trust | 0.07% | 40558 SH | 2026年9月11日 | 每日 |
| RSSL · Global X Funds | 0.06% | 63019 NS | 2026年7月31日 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.06% | 757699 SH | 2026年8月19日 | 每日 |
| SMDX · Tidal Trust III | 0.05% | 4493 NS | 2026年7月31日 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trus... | 0.05% | 54996 SH | 2026年10月1日 | 每日 |
| VBK · VANGUARD INDEX FUNDS | 0.05% | 1728845 SH | 2026年8月19日 | 每日 |
| DFAS · Dimensional ETF Trust | 0.04% | 358850 NS | 2026年7月31日 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.03% | 388986 SH | 2026年8月19日 | 每日 |
| WSML · iShares Trust | 0.03% | 10624 SH | 2026年9月11日 | 每日 |
| FHLC · FIDELITY COVINGTON TRUST | 0.03% | 62331 NS | 2026年7月31日 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.02% | 8379 NS | 2026年7月31日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.02% | 1492431 SH | 2026年8月19日 | 每日 |
| VB · VANGUARD INDEX FUNDS | 0.02% | 2990594 SH | 2026年8月19日 | 每日 |
| IWO · iShares Trust | 0.01% | 115979 SH | 2026年9月11日 | 每日 |
| DFAC · Dimensional ETF Trust | 0.01% | 344253 NS | 2026年7月31日 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.01% | 15340 NS | 2026年7月31日 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.01% | 12627 SH | 2026年8月19日 | 每日 |
| DCOR · Dimensional ETF Trust | 0.01% | 14534 NS | 2026年7月31日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 30125 NS | 2026年7月31日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 47070 NS | 2026年7月31日 | N-PORT |
| ITOT · iShares Trust | 0.00% | 172474 SH | 2026年9月11日 | 每日 |
| TILT · FlexShares Trust | 0.00% | 4536 NS | 2026年7月31日 | N-PORT |
| IWV · iShares Trust | 0.00% | 35356 SH | 2026年9月10日 | 每日 |
| IXUS · iShares Trust | 0.00% | 56854 SH | 2026年9月11日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 4136535 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 10236 SH | 2026年8月19日 | 每日 |
| IJR · iShares Trust | · | 7951677 SH | 2026年9月10日 | 每日 |
| IJT · iShares Trust | · | 716232 SH | 2026年9月9日 | 每日 |
| IJS · iShares Trust | · | 490259 SH | 2026年9月8日 | 每日 |
| IWN · iShares Trust | · | 1129992 SH | 2026年9月11日 | 每日 |
| XJR · iShares Trust | · | 18003 SH | 2026年8月31日 | 每日 |
| ISCB · iShares Trust | · | 5811 SH | 2026年9月11日 | 每日 |
| SMLF · iShares Trust | · | 45624 SH | 2026年9月11日 | 每日 |
NEO 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 16 位分析师
买入
中位数目标
$19.00
+2.9%
4 25.0%
强烈买入
7 43.8%
买入
5 31.2%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
9 位分析师 · 2026-10-02平均目标 $19.72 +6.8%
现在
当前价格 $18.47
最低$16.00
平均值$19.72
最高$35.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| NEO | $1.51B | -49.0 | 10.1% | -14.8% | -12.8% | 43.2% |
| OPCH | $5.00B | 25.1 | 13.0% | 3.7% | 15.4% | 19.3% |
| AVAH | $1.70B | 7.7 | 20.2% | 9.2% | 246.6% | 33.3% |
| GRDN | · | · | 17.9% | 3.4% | 24.8% | 20.2% |
| PRVA | $2.93B | 131.7 | 22.3% | 1.1% | 3.3% | · |
| MD | $1.77B | 11.0 | -4.9% | 8.6% | 20.3% | · |
| ADUS | · | 20.6 | 23.2% | · | · | · |
| WGS | · | · | · | · | · | · |
| ASTH | $1.21B | 53.9 | 56.4% | 0.71% | 3.0% | · |
| AMN | $606M | -6.4 | -8.5% | -3.5% | -15.3% | 28.3% |
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 七月 28, 2026 申报